Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondria-localized glutamic acid-rich protein (MGARP)
- Target
- MGARP
- Molecular classification
- Other (mitochondrial structural and regulatory protein), MGARP is a mitochondrial transmembrane protein, not belonging to any major receptor, ion channel, enzyme, transporter, or transcription factor class[1][3]
01
Overview
Mitochondria-localized glutamic acid-rich protein (MGARP) is a mitochondrial transmembrane protein predominantly expressed in steroidogenic tissues (ovary, adrenal gland, testis) and mitochondrial-rich layers of the retina[1][3]. It plays a key role in maintaining mitochondrial structure and abundance, which is critical for steroid hormone biosynthesis and retinal energetic metabolism. In neuronal cells, MGARP and related proteins (such as HUMMR) regulate mitochondrial transport, especially under hypoxic conditions. MGARP gene expression is tightly controlled, with transcriptional regulation involving Sp1 and estrogen receptor α. While its dysfunction can impair mitochondrial integrity and hormone synthesis, it is not currently a primary target for therapeutic drugs or a standard biomarker in clinical practice[1][3].
- Other names
- OSAPHUMMRC4orf49CESP1CESP-1Ovary-specific acidic proteinCorneal endothelium-specific protein 1Hypoxia up-regulated mitochondrial movement regulatorProtein MGARP
02
Mechanism of action
No drugs are established to target MGARP directly, so mechanisms of drug action are not defined.
03
Biological functions
Maintenance of mitochondrial morphology and abundanceRegulation of mitochondrial movement and organizationSupport of steroid hormone biosynthesisRegulation of cellular metabolism in steroidogenic tissuesContribution to retinal energetics and possibly organization of ion channels on the mitochondrial membrane[1][3]
04
Disease associations
Other (potential involvement in diseases of steroidogenic tissues and visual system)MGARP dysfunction has been associated with impaired mitochondrial integrity, leading to possible defects in steroidogenesis and retinal energetics, but direct causative roles in specific diseases are not well established[1][3]
05
Safety considerations
Not applicableNo therapeutic safety concerns are currently recognized for targeting MGARP
06
Interacting drugs
None established
1 more in the full profile.
07
Biomarkers
Possible candidate as a marker for corneal endothelial cell identity and differentiation, but not widely used clinically[2]MGARP expression is tissue-specific (ovary, adrenal, testis, retina), but it is not currently a recognized biomarker for disease monitoring or patient selection
Beyond the preview
Go deeper on Mitochondria-localized glutamic acid-rich protein (MGARP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitochondria-localized glutamic acid-rich protein (MGARP).